NEUTRALIZATION TITERS OF HIV-1-SPECIFIC MONOCLONAL-ANTIBODIES VARY ACCORDING TO THE BATCH OF PRIMARY HUMAN PERIPHERAL-BLOOD LYMPHOCYTES, BUT DO NOT VARY COORDINATELY
L. Mclain et al., NEUTRALIZATION TITERS OF HIV-1-SPECIFIC MONOCLONAL-ANTIBODIES VARY ACCORDING TO THE BATCH OF PRIMARY HUMAN PERIPHERAL-BLOOD LYMPHOCYTES, BUT DO NOT VARY COORDINATELY, Journal of virological methods, 67(1), 1997, pp. 69-76
Citations number
42
Categorie Soggetti
Virology,"Biochemical Research Methods","Biothechnology & Applied Migrobiology
Human peripheral blood lymphocytes (PBL) were collected from five heal
thy adults under standard conditions and on a number of different occa
sions, and used in neutralization assays of human immunodeficiency vir
us type 1 (HIV-1) strain IIIB with three monoclonal antibodies (mAbs).
Variations in neutralization titre were observed with different batch
es of PBLs with, for example, titres of ICR39.3b ranging from 1/10 to
over 1/40000. However titres were as high, or higher, in PBLs than in
C8166 cells (a human CD4(+) T lymphoblastoid cell line) in 82% (28/34)
of tests made. Most surprising was that neutralization by the three m
Abs did not vary coordinately. In one batch of PBLs the neutralization
titre of one of the mAbs might be increased while that of another mAb
did not increase, or decrease. Thus PBLs could not be described as gi
ving high or low levels of neutralization without reference to a speci
fic mAb. This was not an assay problem as infectivity titres were rela
tively constant (varying by 1 to 1.4 fold with respect to C8166 cells)
, and neutralization titres were reproducible with the same batch of f
rozen PBLs over a three month period. Only one donor gave consistently
low neutralization titres (defined here as 1/200; 2/2 batches tested)
with all three mAbs, but all other donors gave similarly low titres w
ith one of their batches of PBLs. The non-coordinate variation in neut
ralization titre indicates the advisability of using antibodies of sev
eral different specificities in any kind of preventive or therapeutic
immunity. (C) 1997 Elsevier Science B.V.